巨细胞动脉炎的发病机制:靶向治疗如何影响我们对相关机制的理解
本文综述巨细胞动脉炎(GCA)的发病机制,指出固有免疫和适应性免疫均参与初始事件,扩增级联反应参与疾病进展导致血管炎症、重塑和闭塞;由于功能性模型稀缺且有限,特定机制通路在GCA中的作用尚未完全确立;靶向治疗为特定致病机制在GCA发生和维持血管炎症中的相关性提供了功能性概念验证。
要点
- 固有免疫和适应性免疫均被认为在GCA发病初始事件中起重要作用。
- 扩增级联反应参与疾病后续发展和进展,导致血管炎症、重塑和闭塞。
- 靶向治疗为特定致病机制在GCA中的相关性提供功能性概念验证。
核心结论
- 靶向治疗正在为特定致病机制在GCA发生和维持血管炎症中的相关性提供功能性概念验证。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- 固有免疫和适应性免疫系统均被认为在GCA发病机制的初始事件中起重要作用。
- 扩增级联反应参与疾病的后续发展和进展,导致血管炎症、重塑和闭塞。
- 在基因修饰小鼠中建立大血管炎为导致血管炎症的潜在机制提供了一些证据。
- 由于功能性模型的稀缺和局限性,特定机制通路在GCA中的参与尚未完全确立。
临床怎么用
- GCA的治疗正在演变,新型疗法正被纳入GCA治疗格局。
局限性
- 由于功能性模型的稀缺和局限性,特定机制通路在GCA中的参与尚未完全确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
GCA is a chronic granulomatous vasculitis that affects large- and medium-sized vessels. Both the innate and the adaptive immune system are thought to play an important role in the initial events of the pathogenesis of GCA. Amplification cascades are involved in the subsequent development and progression of the disease, resulting in vascular inflammation, remodelling and occlusion. The development of large-vessel vasculitis in genetically modified mice has provided some evidence regarding potential mechanisms that lead to vascular inflammation. However, the participation of specific mechanistic pathways in GCA has not been fully established because of the paucity and limitations of functional models. Treatment of GCA is evolving, and novel therapies are being incorporated into the GCA treatment landscape. In addition, to improve the management of GCA, targeted therapies are providing functional proof of concept of the relevance of particular pathogenic mechanisms in the development of GCA and in sustaining vascular inflammation.
引用
- Terrades-Garcia N, Cid MC. Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved. Rheumatology (Oxford). 2018. PMID: 29982777. doi:10.1093/rheumatology/kex423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。